Tabby Kinyanjui, NP
Acute Care · North Andover, MANPI 1306159496
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,664 of the $6,109 with a category attached, or 76.3%. Otsuka America Pharmaceutical, Inc. accounts for 77.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,779 and has fallen 79.2% since, to $578 in 2025. Among acute care clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $145.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- Johnson & Johnson$690
- AbbVie$498
- Neurocrine Biosciences, Inc.$114
- Teva Pharmaceuticals USA, Inc.$59
What the payments were for
- Speaking & faculty fees$4,66476%
- Food & beverage$1,41523%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $4,748 |
| Johnson & Johnson | 12 | $690 |
| AbbVie(2 entities) | 14 | $498 |
| Neurocrine Biosciences, Inc. | 1 | $114 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$4,664
- SPRAVATO$402
- VRAYLAR$120
- INGREZZA$114
How this compares
$6,109 in reported general payments places this provider in the 95th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $89,103 |
| VraylarCariprazine Hcl | 15 | $26,833 |
| Duloxetine Hcl | 103 | $4,112 |
| Atomoxetine Hcl | 32 | $2,965 |
| Quetiapine Fumarate | 44 | $1,661 |
| Bupropion XlBupropion Hcl | 71 | $1,619 |
| Buspirone Hcl | 82 | $1,467 |
| Oxcarbazepine | 21 | $1,328 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $1,274 |
| Mirtazapine | 53 | $1,154 |
| Trazodone Hcl | 90 | $1,146 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 37 | $1,094 |
| Lorazepam | 198 | $994 |
| Fluoxetine Hcl | 33 | $975 |
| Bupropion Hcl SrBupropion Hcl | 42 | $854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $114 | $89,10311 claims |
| AbbVieVraylar | $498 | $26,83315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 307 acute care providers in Massachusetts.
Other acute care in North Andover
- Margaret ChernaikNorth Andover$1K
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
- Dawn NaylorBoston$13K
- Rebecca RathburnBoston$13K
- Morgan BowdenBoston$11K
- Javier RiveraBoston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.